Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 433

1.

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis.

Wandeler G, Buzzi M, Anderegg N, Sculier D, Béguelin C, Egger M, Calmy A.

Version 2. F1000Res. 2018 Aug 30 [revised 2019 Jan 1];7:1359. doi: 10.12688/f1000research.15995.2. eCollection 2018.

2.

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2019 Apr 15. doi: 10.3851/IMP3310. [Epub ahead of print]

PMID:
30985290
3.

Antiretroviral Drugs Associated with Subclinical Coronary Artery Disease in the Swiss HIV Cohort Study.

Kovari H, Calmy A, Doco-Lecompte T, Nkoulou R, Marzel A, Weber R, Kaufmann PA, Buechel RR, Ledergerber B, Tarr PE; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Apr 8. pii: ciz283. doi: 10.1093/cid/ciz283. [Epub ahead of print]

PMID:
30958888
4.

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Mar 7. pii: ciz178. doi: 10.1093/cid/ciz178. [Epub ahead of print]

PMID:
30843028
5.

A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.

Kusejko K, Bachmann N, Chaudron SE, Nguyen H, Braun DL, Hampel B, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

J Infect Dis. 2019 Mar 4. pii: jiz093. doi: 10.1093/infdis/jiz093. [Epub ahead of print]

PMID:
30835292
6.

Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection.

Carlisle LA, Turk T, Kusejko K, Metzner KJ, Leemann C, Schenkel C, Bachmann N, Posada S, Beerenwinkel N, Böni J, Yerly S, Klimkait T, Perreau M, Braun DL, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

J Infect Dis. 2019 Mar 4. pii: jiz094. doi: 10.1093/infdis/jiz094. [Epub ahead of print]

PMID:
30835266
7.

Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort.

Gencer B, Pagano S, Vuilleumier N, Satta N, Delhumeau-Cartier C, Meier C, Bavamian S, Montecucco F, Mach F, Calmy A.

Atherosclerosis. 2019 Feb 20. pii: S0021-9150(19)30093-0. doi: 10.1016/j.atherosclerosis.2019.02.015. [Epub ahead of print]

PMID:
30827714
8.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group .

J Antimicrob Chemother. 2019 Feb 11. doi: 10.1093/jac/dkz011. [Epub ahead of print]

PMID:
30753724
9.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
10.

Female Genital Schistosomiasis and HIV: Research Urgently Needed to Improve Understanding of the Health Impacts of This Important Coinfection.

OʼBrien DP, Ford N, Djirmay AG, Calmy A, Vitoria M, Jensen TO, Christinet V.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):489-493. doi: 10.1097/QAI.0000000000001957.

PMID:
30730357
11.

[Diagnosis, prevention and treatment of HIV : what's new in 2018 ?]

D'Incau S, Viala B, Ciuffi A, Cavassini M, Calmy A.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):107-112. French.

PMID:
30629381
12.

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Biver E, Calmy A, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Ferrari S, Frey D, Kressig RW, Lamy O, Lippuner K, Suhm N, Meier C.

Osteoporos Int. 2019 Jan 2. doi: 10.1007/s00198-018-4794-0. [Epub ahead of print]

PMID:
30603840
13.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.

Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29.

14.

Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.

Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study .

J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436.

PMID:
30476115
15.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
16.

Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient.

Nabergoj M, Nawej Tshikung O, Tsopra O, Ghinescu A, Samii K, Calmy A.

Ann Hematol. 2019 May;98(5):1317-1318. doi: 10.1007/s00277-018-3511-6. Epub 2018 Oct 17. No abstract available.

PMID:
30328487
17.

Anti-inflammatory therapy in well controlled HIV infection.

Tarr PE, Calmy A.

Lancet HIV. 2018 Oct;5(10):e538-e539. doi: 10.1016/S2352-3018(18)30250-9. Epub 2018 Sep 23. No abstract available.

PMID:
30257801
18.

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.

Kusejko K, Kadelka C, Marzel A, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Virus Evol. 2018 Sep 18;4(2):vey024. doi: 10.1093/ve/vey024. eCollection 2018 Jul. Review.

19.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study.

Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10.

PMID:
30202088
20.

Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study.

Bouatou Y, Gayet Ageron A, Bernasconi E, Battegay M, Hoffmann M, Staehelin C, Merz L, Kovari H, Fux C, de Seigneux S, Calmy A; Swiss HIV Cohort Study.

Kidney Int Rep. 2018 May 8;3(5):1089-1099. doi: 10.1016/j.ekir.2018.04.014. eCollection 2018 Sep.

Supplemental Content

Loading ...
Support Center